ENDP : Analysis & Opinions

  1. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  2. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  3. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  4. Impax Launches Opana ER Generic - Analyst Blog

    January 7, 2013
    Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. (IPXL), a specialty pharmaceutical company, recently ...
  5. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  6. Endo Health Beats on All Fronts - Analyst Blog

    August 9, 2012
    Endo Health Solutions' (ENDP) second quarter 2012 earnings (excluding special items) of $1.27 per share beat the Zacks Consensus ...
  7. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  8. Endo And Forest – Dumpster-Diving In Pharma

    September 21, 2011
    Endo and Forest have problems; however, the valuations seem excessively low.
Trading Center